Demographics of the overall cohort (n = 65)
| Demographics . | Total cohort (n = 65) . |
|---|---|
| Sex | |
| Male | 39 (60.0) |
| Female | 26 (40.0) |
| Age, y | |
| Median age at diagnosis (range) | 64 (37-83) |
| <40 | 1 (1.5) |
| 40-49 | 5 (7.7) |
| 50-59 | 13 (20.0) |
| 60-69 | 26 (40.0) |
| 70-79 | 15 (23.1) |
| 80+ | 5 (7.7) |
| Diagnosis | |
| e-MF | 6 (9.2) |
| SS* | 59 (90.8) |
| LCT at diagnosis | 3 (4.6) |
| Stage at diagnosis | |
| IA | 0 (0.0) |
| IB | 5 (7.7) |
| IIA | 1 (1.5) |
| IIB | 1 (1.5) |
| IIIA | 15 (23.1) |
| IIIB | 12 (18.5) |
| IVA1 | 27 (41.5) |
| IVA2 | 1 (1.5) |
| IVB | 2 (3.1) |
| Tumor skin score | |
| T1 | 0 (0.0) |
| T2 | 6 (9.2) |
| T3 | 0 (0.0) |
| T4 | 59 (90.8) |
| Nodal involvement | |
| N0 | 30 (46.1) |
| N1 | 26 (40.0) |
| N2 | 4 (6.2) |
| N3 | 1 (1.5) |
| Nx | 4 (6.2) |
| Visceral involvement | |
| M0 | 63 (96.9) |
| M1 | 2 (3.1) |
| Blood involvement* | |
| B0 | 16 (24.6) |
| B0a | 1 (1.5) |
| B0b | 2 (3.1) |
| B1 | 17 (26.2) |
| B2 | 29 (44.6) |
| Clonal arrangement (n = 50) | |
| Monoclonal | 45 (69.2) |
| Polyclonal | 4 (6.2) |
| Oligoclonal | 1 (1.5) |
| Unknown | 15 (23.1) |
| Median number of treatment lines (range) | 4 (1-13) |
| ECP device used | |
| UVAR-XTS | 12 (18.5) |
| Therakos CELLEX | 47 (72.3) |
| Both | 6 (9.2) |
| Demographics . | Total cohort (n = 65) . |
|---|---|
| Sex | |
| Male | 39 (60.0) |
| Female | 26 (40.0) |
| Age, y | |
| Median age at diagnosis (range) | 64 (37-83) |
| <40 | 1 (1.5) |
| 40-49 | 5 (7.7) |
| 50-59 | 13 (20.0) |
| 60-69 | 26 (40.0) |
| 70-79 | 15 (23.1) |
| 80+ | 5 (7.7) |
| Diagnosis | |
| e-MF | 6 (9.2) |
| SS* | 59 (90.8) |
| LCT at diagnosis | 3 (4.6) |
| Stage at diagnosis | |
| IA | 0 (0.0) |
| IB | 5 (7.7) |
| IIA | 1 (1.5) |
| IIB | 1 (1.5) |
| IIIA | 15 (23.1) |
| IIIB | 12 (18.5) |
| IVA1 | 27 (41.5) |
| IVA2 | 1 (1.5) |
| IVB | 2 (3.1) |
| Tumor skin score | |
| T1 | 0 (0.0) |
| T2 | 6 (9.2) |
| T3 | 0 (0.0) |
| T4 | 59 (90.8) |
| Nodal involvement | |
| N0 | 30 (46.1) |
| N1 | 26 (40.0) |
| N2 | 4 (6.2) |
| N3 | 1 (1.5) |
| Nx | 4 (6.2) |
| Visceral involvement | |
| M0 | 63 (96.9) |
| M1 | 2 (3.1) |
| Blood involvement* | |
| B0 | 16 (24.6) |
| B0a | 1 (1.5) |
| B0b | 2 (3.1) |
| B1 | 17 (26.2) |
| B2 | 29 (44.6) |
| Clonal arrangement (n = 50) | |
| Monoclonal | 45 (69.2) |
| Polyclonal | 4 (6.2) |
| Oligoclonal | 1 (1.5) |
| Unknown | 15 (23.1) |
| Median number of treatment lines (range) | 4 (1-13) |
| ECP device used | |
| UVAR-XTS | 12 (18.5) |
| Therakos CELLEX | 47 (72.3) |
| Both | 6 (9.2) |
The difference between the number of patients who received a diagnosis of SS (n = 59) and those who had B2 disease at diagnosis (n = 29) was due to (i) the varying criteria used for a diagnosis of SS during the course of the study according to the diagnostic criteria used at the time of commencing ECP (ie, utilization of CD4:8 ratio by flow cytometry and prior to the updated TNMB staging by Olsen et al in 200726 ) and (ii) some patients without a detectable clone in the blood at diagnosis subsequently detected a clone in the peripheral blood at a later date.